Novo Nordisk next-generation obesity drug beats Zepbound in new trial
The result pits Novo's experimental candidate directly against Eli Lilly's tirzepatide, currently the most effective approved weight-loss injection.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 28 08:23 ETSource: The Hill
The wire
- 01The Hill reports that Novo Nordisk's next-generation weight-loss drug outperformed Eli Lilly's Zepbound (tirzepatide) in a new clinical trial.
- 02A head-to-head win over tirzepatide would shift prescribing and payer conversations for clinicians and telehealth operators handling incretin demand.
- 03Full trial data, safety and tolerability details, and any regulatory filing timeline remain to be published and peer reviewed.
From the source
Read at thehill.comNovo Nordisk’s next-gen weight loss drug outperforms Zepbound in new trial
